FIELD: medicine, oncology, and therapy.
SUBSTANCE: group of inventions is intended for the treatment of liver cancer. Talimogen lagerparepvec is used to treat a subject having liver cancer that hardly responds to standard systemic cancer therapy, progresses during standard systemic cancer therapy, and/or is resistant to standard systemic cancer therapy; talimogen lagerparepvec is administered to the subject in combination with pembrolizumab. Also the following is provided: the use of pembrolizumab for the treatment of a subject having liver cancer that hardly responds to standard systemic cancer therapy, progresses during standard systemic cancer therapy, and/or is resistant to standard systemic cancer therapy; pembrolizumab is administered to the subject in combination with the talimogen lagerparepvec. In other embodiments, the use of talimogen lagerparepvec and pembrolizumab in combination is provided for the treatment of a subject having liver cancer that hardly responds to standard systemic cancer therapy, progresses during standard systemic cancer therapy, and/or is resistant to standard systemic cancer therapy; the use of talimogen lagerparepvec for the treatment of a subject having liver cancer who has failed to achieve a sustained response after prior therapy with pembrolizumab, wherein talimogen lagerparepvec is administered to the subject in combination with pembrolizumab; the use of pembrolizumab for the treatment of a subject having liver cancer who has failed to achieve a sustained response following prior therapy with pembrolizumab, wherein pembrolizumab is administered to the subject in combination with the talimogen lagerparepvec; and the use of talimogen lagerparepvec and pembrolizumab in combination for the treatment of a subject with liver cancer who has failed to achieve a sustained response following prior pembrolizumab therapy.
EFFECT: use of the group of inventions makes it possible to increase the effectiveness of the treatment of liver cancer.
22 cl, 3 dwg, 1 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS OF TREATING CERVICAL CANCER BY ADMINISTERING INHIBITOR PD-1 | 2021 |
|
RU2833461C1 |
| COMBINATION OF HDAC INHIBITOR AND ANTI-PD-1 ANTIBODY FOR TREATMENT OF CANCER | 2016 |
|
RU2796903C2 |
| USE OF INHIBITORS OF IMMUNE CONTROL POINTS IN NEW GROWTHS OF CENTRAL NERVOUS SYSTEM | 2015 |
|
RU2726996C1 |
| METHODS OF TREATING CANCER USING ANTI-PD-1 ANTIBODIES AND ANTI-CTLA4 ANTIBODIES | 2019 |
|
RU2825835C2 |
| COMBINATION OF PD-1 ANTAGONIST AND ERIBULIN FOR TREATING CANCER | 2016 |
|
RU2737216C2 |
| MULTI-SPECIFIC ANTIBODIES INTENDED FOR USE IN TREATMENT OF URINARY TRACT NEOPLASM | 2017 |
|
RU2766358C2 |
| PD-1/PD-L1 INHIBITORS FOR TREATING CANCER | 2016 |
|
RU2742312C1 |
| CONTROL POINT INHIBITOR AND WHOLE-CELL MICROBACTERIA FOR USE IN TREATING ONCOLOGICAL DISEASE | 2014 |
|
RU2719934C2 |
| TIGIT ANTIBODY ADMINISTRATION REGIMEN FOR TREATING CANCER | 2019 |
|
RU2833669C2 |
| USE OF BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND MUC16 AND CD3, IN COMBINATION WITH COSTIMULATION 4-1BB | 2020 |
|
RU2822091C2 |
